Filing Body
Page 1: UNITED STATES
Page 2: BRISTOL-MYERS SQUIBB COMPANY
Page 3: PART I FINANCIAL INFORMATION
Page 4: BRISTOL-MYERS SQUIBB COMPANY
Page 5: BRISTOL-MYERS SQUIBB COMPANY
Page 6: BRISTOL-MYERS SQUIBB COMPANY
Page 7: Note 1. BASIS OF PRESENTATION AND NEW ACCOUNTING STANDARDS
Page 8: Note 3. ALLIANCES AND COLLABORATIONS
Page 9: Otsuka
Page 10: Erbitux*
Page 11: Pfizer
Page 12: Note 4. ACQUISITIONS
Page 13: Note 5. RESTRUCTURING
Page 14: Note 7. EARNINGS PER SHARE
Page 15: Available-For-Sale Securities and Cash Equivalents
Page 16: Qualifying Hedges
Page 17: Note 9. RECEIVABLES
Page 18: Note 11. PROPERTY, PLANT AND EQUIPMENT
Page 19: Plavix
Page 20: Note 15. EMPLOYEE STOCK BENEFIT PLANS
Page 21: Plavix*
Page 22: Baraclude
Page 23: PRICING, SALES AND PROMOTIONAL PRACTICES LITIGATION AND INVESTIGATIONS
Page 24: Reglan*
Page 25: OTHER PROCEEDINGS
Page 26: Item 2. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Page 27: Product and Pipeline Developments
Page 28: Erbitux*
Page 29: Plavix*
Page 30: N/A
Page 31: N/A
Page 32: Plavix*
Page 33: Erbitux*
Page 34: Estimated End-User Demand
Page 35: Luftal
Page 36: Plavix*
Page 37: N/A
Page 38: Income Taxes
Page 39: Plavix*
Page 40: Operating Activities
Page 41: CRITICAL ACCOUNTING POLICIES
Page 42: Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Page 43: Item 6. EXHIBITS
Page 44: N/A
Exhibits
EX-10.B
EX-12
EX-31.A
EX-31.B
EX-32.A
EX-32.B
EX-101.INS
EX-101.SCH
EX-101.CAL
EX-101.DEF
EX-101.LAB
EX-101.PRE
Interactive Data
XBRL Viewer